Literature DB >> 29368377

Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria.

L Curto-Barredo1, J Spertino1, I Figueras-Nart1, V Expósito-Serrano1, A Guilabert1, G Melé-Ninot1, X Cubiró1, M Bonfill-Ortí1, J Garcias-Ladaria1, M Villar1, X García-Navarro1, I Bielsa-Marsol1, M Vilavella1, G Aparicio1, C Baliu-Piqué1, A Álvarez1, N Lamas-Domenech1, X Duran-Jordà1, E Serra-Baldrich1, A Giménez-Arnau1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29368377     DOI： 10.1111/bjd.16379

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  4 in total

Review 1.  Targeted Therapy for Chronıc Spontaneous Urtıcarıa: Ratıonale and Recent Progress.

Authors:  Ana M Giménez-Arnau; Andaç Salman
Journal:  Drugs       Date:  2020-11       Impact factor: 9.546

2.  Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both.

Authors:  Yudi Chen; Miao Yu; Xiaojie Huang; Ping Tu; Peikun Shi; Marcus Maurer; Zuotao Zhao
Journal:  World Allergy Organ J       Date:  2021-01-05       Impact factor: 4.084

Review 3.  Monoclonal Antibodies in Treating Chronic Spontaneous Urticaria: New Drugs for an Old Disease.

Authors:  Sara Manti; Alessandro Giallongo; Maria Papale; Giuseppe Fabio Parisi; Salvatore Leonardi
Journal:  J Clin Med       Date:  2022-07-30       Impact factor: 4.964

Review 4.  Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence.

Authors:  Martin Metz; Zahava Vadasz; Emek Kocatürk; Ana M Giménez-Arnau
Journal:  Clin Rev Allergy Immunol       Date:  2020-08       Impact factor: 8.667
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.